Clinical Trial

A Phase I Study of BPI-16350 in Patients with Advanced Solid Tumor

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated January 27, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
This was an open-label Phase I study. The primary objective of the study was to assess safety, tolerability, efficacy, and pharmacokinetic characteristics of BPI-16350 in different dose groups.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2018-12-29; most recent amendment 2025-01-22.
Status change: Recruiting → Active, Not Recruiting 2025-01-22
Status change: Not Yet Recruiting → Recruiting 2022-06-15
Trial Details
NCT Number NCT03791112
Lead Sponsor Betta Pharmaceuticals Co., Ltd.
Conditions Advanced Solid Cancer
Enrollment 54 participants
Start Date 2019-07-18
Primary Completion 2025-12 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-01-27